Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.248 EUR | 0.00% | +0.48% | -3.11% |
Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.11% | 43.75M | - | ||
+17.06% | 121B | B+ | ||
+13.71% | 107B | B+ | ||
-5.75% | 24.82B | B+ | ||
+1.69% | 22.48B | B | ||
-10.09% | 18.32B | A- | ||
-40.52% | 16.33B | A- | ||
-14.42% | 15.31B | B | ||
+3.19% | 14.08B | C+ | ||
+24.11% | 11.74B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ABNX Stock
- Ratings ABIONYX Pharma